

US Family Health Plan

Prior Authorization Request Form for fremanezumab-vfrm (**Ajovy**)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be **faxed** to **855-273-5735**

OR

The patient may attach the completed form to the prescription and **mail** it to:

Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? **Call 1-877-880-7007**

Prior authorization for initial therapy will approve for 6 months. Prior authorization for continuation of therapy does not expire. For renewal of therapy an initial TRICARE/USFHP prior authorization approval is required.

usfamilyhealth.org/rx-pa

Step 1 Please complete patient and physician information (please print):

Patient Name: _____ Address: _____ Sponsor ID #: _____ Date of Birth: _____	Physician Name: _____ Address: _____ Phone #: _____ Secure Fax #: _____
--	--

Step 2 Please complete the clinical assessment:

1. Has the patient received this medication under the TRICARE benefit in the last 6 months? <i>Please choose "No" if the patient did not previously have a TRICARE approved PA for Ajovy.</i>	<input type="checkbox"/> Yes (subject to verification) Proceed to question 18	<input type="checkbox"/> No Proceed to question 2
2. The provider acknowledges that Emgality 120 mg is the DoD's preferred injectable CGRP inhibitor and is available without a prior authorization.	<input type="checkbox"/> Acknowledged Proceed to question 3	
3. Has the patient tried and failed Emgality 120 mg?	<input type="checkbox"/> Yes Proceed to question 6	<input type="checkbox"/> No Proceed to question 4
4. Has the patient experienced an adverse reaction to Emgality 120 mg that is not expected to occur with Ajovy?	<input type="checkbox"/> Yes Proceed to question 6	<input type="checkbox"/> No Proceed to question 5
5. Does the patient have a contraindication to Emgality 120 mg?	<input type="checkbox"/> Yes Proceed to question 6	<input type="checkbox"/> No STOP Coverage not approved
6. Is this medication being prescribed by or in consultation with a neurologist	<input type="checkbox"/> Yes Proceed to question 7	<input type="checkbox"/> No STOP Coverage not approved
7. Is the patient 18 years of age or older?	<input type="checkbox"/> Yes Proceed to question 8	<input type="checkbox"/> No STOP Coverage not approved
8. Is the patient pregnant or actively trying to become pregnant?	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Proceed to question 9

US Family Health Plan Prior Authorization Request Form for
fremanezumab-vfrm (**Ajovy**)

<p>9. What is the indication or diagnosis?</p>	<input type="checkbox"/> Chronic migraines - Proceed to question 13 <input type="checkbox"/> Episodic migraines - Proceed to question 10 <input type="checkbox"/> All other diagnosis or indications – STOP Coverage not approved	
<p>10. Has the patient experienced three consecutive months of 8 migraine days per month?</p>	<input type="checkbox"/> Yes Proceed to question 13	<input type="checkbox"/> No Proceed to question 11
<p>11. Has the patient experienced three consecutive months of 4-7 migraine days per month?</p>	<input type="checkbox"/> Yes Proceed to question 12	<input type="checkbox"/> No STOP Coverage not approved
<p>12. Does the patient have at least moderate disability shown by Migraine Disability Assessment (MIDAS) Test score greater than 11 or Headache Impact Test-6 (HIT-6) score greater than 50?</p>	<input type="checkbox"/> Yes Proceed to question 13	<input type="checkbox"/> No STOP Coverage not approved
<p>13. Will the patient use other prophylaxis calcitonin gene-related peptide (CGRP) inhibitors (such as Aimovig or Emgality) in combination with the requested medication? Note: This does not include the CGRP targeted abortive inhibitors (for example, another "gepant", Nurtec or Ubrelvy).</p>	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Proceed to question 14
<p>14. Please note for the following questions, formulary migraine prophylactic drug classes include:</p> <ul style="list-style-type: none"> • Prophylactic antiepileptic medications: valproate, divalproic acid, topiramate; • Prophylactic beta-blocker medications, examples include, metoprolol, propranolol, atenolol, nadolol, timolol; • Prophylactic antidepressants: amitriptyline, duloxetine, nortriptyline, venlafaxine. 	<p align="center">Proceed to question 15</p>	
<p>15. Has the patient tried at least ONE drug from TWO of the above migraine prophylactic drug classes?</p>	<input type="checkbox"/> Yes Proceed to question 16	<input type="checkbox"/> No Proceed to question 17
<p>16. Has the patient experienced intolerance or failure after an adequate 2 month trial of at least ONE drug from TWO of the above migraine prophylactic drug classes?(An adequate trial is generally considered to be 6 to 8 weeks in duration because of the amount of time required to achieve maximal benefit with therapy.)</p>	<input type="checkbox"/> Yes Sign and date below	<input type="checkbox"/> No STOP Coverage not approved
<p>17. Does the patient have a contraindication to at least ONE drug from TWO of the above migraine prophylactic drug classes?</p>	<input type="checkbox"/> Yes Sign and date below	<input type="checkbox"/> No STOP Coverage not approved
<p>18. Has the patient had a reduction in mean monthly headache days of GREATER THAN OR EQUAL TO 50% relative to the pretreatment baseline (as shown by patient diary documentation or healthcare provider attestation)?</p>	<input type="checkbox"/> Yes Sign and date below	<input type="checkbox"/> No Proceed to question 19

US Family Health Plan Prior Authorization Request Form for
fremanezumab-vfrm (**Ajovy**)

<p>19. Has the patient shown a clinically meaningful improvement in ANY of the following validated migraine-specific patient-reported outcome measures:</p> <p>A) Migraine Disability Assessment (MIDAS):</p> <ul style="list-style-type: none">• a reduction of 5 points or more when baseline score is 11-20 or• a reduction of 30% or more when baseline score is greater than 20; <p>B) Headache Impact Test (HIT-6): a reduction of 5 points or more;</p> <p>C) Migraine Physical Functional Impact Diary (MPFID): a reduction of 5 points or more</p>	<p><input type="checkbox"/> Yes Sign and date below</p>	<p><input type="checkbox"/> No STOP Coverage not approved</p>
--	---	--

Step 3 I certify the above is true to the best of my knowledge. Please sign and date:

Prescriber Signature

Date